SEARCH

SEARCH BY CITATION

References

  • Abramoff M. D., Magelhaes P. J. and Ram S. J. (2004) Image processing with ImageJ. Biophotonics Int. 11, 3642.
  • Agadjanyan M. G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T. and Cribbs D. H. (2005) Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174, 15801586.
  • Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D. and Hyman B. T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22, 78737878.
  • Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916919.
  • Bard F., Barbour R., Cannon C. et al. (2003) Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. U S A 100, 20232028.
  • Birmingham K. and Frantz S. (2002) Set back to Alzheimer vaccine studies. Nat. Med. 8, 199200.
  • Chang L., Bakhos L., Wang Z., Venton D. L. and Klein W. L. (2003) Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20, 305313.
  • Chromy B. A., Nowak R. J., Lambert M. P. et al. (2003) Self-assembly of Abeta (1–42) into globular neurotoxins. Biochemistry 42, 12 74912 760.
  • Cribbs D. H., Ghochikyan A., Vasilevko V. et al. (2003) Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15, 505514.
  • DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-A beta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. U S A 98, 88508855.
  • Dodart J. C., Bales K. R., Gannon K. S. et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452457.
  • Ferrer I., Boada R. M., Sanchez Guerra M. L., Rey M. J. and Costa-Jussa F. (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14, 1120.
  • Frenkel D., Katz O. and Solomon B. (2000) Immunization against Alzheimer's beta-amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. U S A 97, 11 45511 459.
  • Gelinas D. S., DaSilva K., Fenili D., George-Hyslop P. and McLaurin J. (2004) Immunotherapy for Alzheimer's disease. Proc. Natl Acad. Sci. U S A 101 Suppl 2, 14 65714 662.
  • Georganopoulou D. G., Chang L., Nam J. M., Thaxton C. S., Mufson E. J., Klein W. L. and Mirkin C. A. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. U S A 102, 22732276.
  • Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., Krafft G. A. and Klein W. L. (2003) Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. U S A 100, 10 41710 422.
  • Haes A. J., Chang L., Klein W. L. and Van Duyne R. P. (2005) Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J. Am. Chem. Soc. 127, 22642271.
  • Hardy J. and Selkoe D. J. (2002) Medicine – The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353356.
  • Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547554.
  • Itagaki S., McGeer P. L., Akiyama H., Zhu S. and Selkoe D. (1989) Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 24, 173182.
  • Janus C., Pearson J., McLaurin J. et al. (2000) Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979982.
  • Jensen M., Hartmann T., Engvall B. et al. (2000) Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med. 6, 291302.
  • Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W. and Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • Kim K. S., Wen G., Bancher C., Chen J. C., Sapienza V. J., Hong H. andandWisniewski H. M. (1990) Quantitation of amyloid β– protein with two monoclonal antibodies. Neurosci. Res. Commun. 7, 113122.
  • Klein W. L. (2000) Abeta toxicity in Alzheimer's disease, in Molecular Mechanisms of Neurodegenerative Diseases (Chesselet, M.-F., eds), pp. 147. Humana Press, Los Angeles, USA.
  • Klein W. L. (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345352.
  • Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S. and Ashe K. H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 63316335.
  • Lacor P. N., Buniel M. C., Chang L. et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 24, 10 19110 200.
  • Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. U S A 95, 64486453.
  • Lambert M. P., Viola K. L., Chromy B. A., Chang L., Morgan T. E. Yu .J Venton D. L. Krafft G. A. Finch C. E. and Klein W. L. (2001) Vaccination with soluble Abeta oligomers generates toxicity- neutralizing antibodies. J. Neurochem. 79, 595605.
  • Lee E. B., Leng L. Z., Zhang B., Kwong L., Trojanowski J. Q., Abel T. and Lee V. M. Y. (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 281, 42924299.
  • Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M. and Ashe K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352357.
  • Li A. and Fenselau C. (2004) Contact regions in the dimer of Alzheimer beta-amyloid domain [1–28] studied by mass spectrometry. Eur J. Mass Spectrom. (Chichester, Eng) 10, 309316.
  • Ma Q. L., Lim G. P., Harris-White M. E., Yang F. S., Ambegaokar S. S., Glabe C. G., Teter B., Frautschy S. A. and Cole G. M. (2006) Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3 beta activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res. 83, 374384.
  • Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. and Schenk D. (2005) A beta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64, 129131.
  • McLaurin J., Cecal R., Kierstead M. E. et al. (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4–10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 12631269.
  • Morgan D. and Gitter B. D. (2004) Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. Neurobiol. Aging 25, 605608.
  • Morgan D., Diamond D. M., Gottschall P. E. et al. (2000) Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982985.
  • Nicoll J. A., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448452.
  • Oddo S., Caccamo A., Tran L., Lambert M. P., Glabe C. G., Klein W. L. and LaFerla F. M. (2006) Temporal profile of amyloid-beta (A beta) oligomerization in an in vivo model of Alzheimer disease – a link between Abeta and tau pathology. J. Biol. Chem. 281, 15991604.
  • Orgogozo J. M., Gilman S., Dartigues J. F. et al. (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 4654.
  • Savage M. J., Trusko S. P., Howland D. S., Pinsker L. R., Mistretta S., Reaume A. G., Greenberg B. D., Siman R. and Scott R. W. (1998) Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 18, 17431752.
  • Schenk D. (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824828.
  • Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature 400, 173177.
  • Schenk D., Hagen M. and Seubert P. (2004) Current progress in beta-amyloid immunotherapy. Curr. Opin. Immunol. 16, 599606.
  • Seubert P., Vigo-Pelfrey C., Esch F. et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325327.
  • Solomon B. (2003) Immunological approach for the treatment of Alzheimer's disease. J. Mol. Neurosci. 20, 283286.
  • Stine W. B.Jr, Dahlgren K. N., Krafft G. A. and LaDu M. J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11 61211 622.
  • Wang H. W., Pasternak J. F., Kuo H. et al. (2002) Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133140.
  • Wang Q., Walsh D. M., Rowan M. J., Selkoe D. J. and Anwyl R. (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24, 33703378.
  • Wyss-Coray T., Loike J. D., Brionne T. C., Lu E., Anankov R., Yan F. R., Silverstein S. C. and Husemann J. (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9, 453457.
  • Youm J. W., Kim H., Han J. H. et al. (2005) Transgenic potato expressing Abeta reduce Abeta burden in Alzheimer's disease mouse model. FEBS Lett. 579, 67376744.